ALT New Zealand Ltd v Attorney-General

Link copied
Case Copied 10 min read

IN THE HIGH COURT OF NEW ZEALAND WELLINGTON REGISTRY

I TE KŌTI MATUA O AOTEAROA TE WHANGANUI-A-TARA ROHE

CIV-2023-485-146

[2024] NZHC 140

UNDER the Judicial Review Procedure Act 2016 and the Declaratory Judgments Act 1908

IN THE MATTER

of an application for judicial review, and for declarations under the Declaratory Judgments Act 1908, in respect of cl 15 and Sch 5 to the Smokefree Environments and Regulated Products Regulations 2021

BETWEEN

ALT NEW ZEALAND LTD

First Applicant

AND

VEC LTD

Second Applicant

AND

MYRIAD PHARMACEUTICALS LTD

Third Applicant

AND

ATTORNEY-GENERAL

Respondent

On the Papers

Counsel:

D A Laurenson KC and L I van Dam for Applicants H Ebersohn and V A Howell for Respondent

Judgment:

9 February 2024


COSTS JUDGMENT OF ELLIS J


ALT NZ LTD v VEC LTD [2024] NZHC 140 [9 February 2024]

[1]    In late March 2023, ALT New Zealand Ltd, VEC Ltd and Myriad Pharmaceuticals Ltd (together, the applicants) brought proceedings against the Director-General of Health regarding the interpretation of cl 15 of sch 5 of the Smokefree Environments and Regulated Products Regulations 2021. At issue was whether the cl 15 regulated the strength of nicotine in nicotine salt (as the applicants contended) or of the nicotine salt itself.1 A hearing on 16 August 2023 was allocated.

[2]    On 26 May 2023 the Ministry of Health (the Ministry) advised the Minister of Health (the Minister) of its intention to concede that cl 15 was to be interpreted as submitted by the applicants.2

[3]    On 23 June counsel for the Ministry filed a memorandum seeking an adjournment of the 16 August fixture because the Ministry was proposing to amend the regulations to “clarify” the meaning of cl 15 and were consulting on that proposal. The proposed amendment would (and later, did):

… regulate on the basis of nicotine strength (which is what the appellants [sic] seek). This amendment is proposed to set the concentration of nicotine strength in products containing nicotine salts at 28.5mg/ml.

[4]    This memorandum prompted me to inquire, in a Minute dated 3 July 2023, whether the Ministry now agreed that the applicants’ grounds of review were made out and that a declaration to that effect could be made.3 The Ministry advised in response that the Ministry did not agree to a declaration being made “at this time”.

[5]    The applicants opposed any adjournment of the hearing and denied that the interpretation issue was moot. I agreed with that submission and declined the adjournment application.4


1      To the extent this judgment requires the reader to understand the merits of the interpretation issue in any detail, it should be read alongside my decision in ALT New Zealand Ltd v Attorney-General [2023] NZHC 2300.

2      This advice was referred to in a later affidavit by the Minister.

3      ALT  New  Zealand  Ltd  v  Director-General  of  Health  HC  Wellington  CIV-2023-485-146,  3 July 2023 (Minute of Ellis J).

4      ALT New Zealand  Ltd  v  Director-General  of  Health  HC  Wellington  CIV-2023-485-146,  10 July 2023 (Minute of Ellis J).

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read ALT New Zealand Ltd v Attorney-General and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2024] NZHC 140
Decision Date

CaseChat Overview and Summary

In the case of ALT New Zealand Ltd v Attorney-General, the applicants sought judicial review of the interpretation of cl 15 of sch 5 of the Smokefree Environments and Regulated Products Regulations 2021. The applicants contended that cl 15 regulated the strength of nicotine in nicotine salt, rather than the nicotine salt itself. The case proceeded to a substantive hearing, however, the Crown conceded the interpretation point, and a declaration was made by consent that cl 15 meant that the strength of nicotine in a nicotine salt vaping substance must not exceed 50 mg/mL.

The applicants now sought indemnity costs of $149,387.50 on the basis that the Ministry knew or ought to have known from the outset that the applicants’ interpretation of cl 15 was correct. The Attorney-General opposed the indemnity costs, submitting that scale 2B costs plus disbursements were appropriate, with a further contribution of $20,000. The court held that the Ministry’s position on the meaning of cl 15 at the start of the proceedings could not be described as a hopeless case. The court also found that the two-month delay between the Ministry advising the Minister of its intention to concede and formally conceding the proceeding was reasonable. The court ordered that the respondent pay the applicants’ costs on a 2B basis, together with an uplift of $20,000 and disbursements of $2,020.

In summary, the court found that the Ministry’s position on the meaning of cl 15 at the start of the proceedings could not be described as a hopeless case and that the two-month delay between the Ministry advising the Minister of its intention to concede and formally conceding the proceeding was reasonable. As a result, the court ordered that the respondent pay the applicants’ costs on a 2B basis, together with an uplift of $20,000 and disbursements of $2,020.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established